参考文献/References:
[1] Ramieri MT, Murari R, Botti C, et al. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma[J]. Anticancer Res, 2010, 30(4):1287-1292.
[2] Carlsson J. Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors[J]. Tumour Biol, 2012, 33(3):653-659. DOI:10.1007/s13277-011-0307-x.
[3] Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer[J]. J Clin Oncol, 2005, 23(16):3676-3685. DOI:10.1200/JCO. 2005. 07. 032.
[4] Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742):687-697. DOI:10.1016/S0140-6736(10)61121-X.
[5] Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer[J]. Biochim Biophys Acta, 1994, 1198(2/3):165-184.
[6] Dean-Colomb W, Esteva FJ. Her2-positive breast cancer:herceptin and beyond[J]. Eur J Cancer, 2008, 44(18):2806-2812. DOI:10.1016/j. ejca. 2008. 09. 013.
[7] Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785):177-182.
[8] Shen K, Ma X, Zhu C, et al. Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer:a Meta-analysis[J/OL]. Sci Rep, 2016, 6:23262[2015-12-23]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793192. DOI:10.1038/srep23262.
[9] Bell R, Verma S, Untch M, et al. Maximizing clinical benefit with trastuzumab[J]. Semin Oncol, 2004, 31(5 Suppl 10):S35-44. DOI:10.1053/j.seminoncol. 2004. 07. 020.
[10] Nord K, Nilsson J, Nilsson B, et al. A combinatorial library of an alpha-helical bacterial receptor domain[J]. Protein Eng, 1995, 8(6):601-608. DOI:10.1093/protein/8. 6. 601.
[11] Miao Z, Levi J, Cheng Z. Protein scaffold-based molecular probes for cancer molecular imaging[J]. Amino Acids, 2011, 41(5):1037-1047. DOI:10.1007/s00726-010-0503-9.
[12] Nilsson FY, Tolmachev V. Affibody molecules:new protein domains for molecular imaging and targeted tumor therapy[J]. Curr Opin Drug Discov Devel, 2007, 10(2):167-175.
[13] Orlova A, Feldwisch J, Abrahmsén L, et al. Update:affibody molecules for molecular imaging and therapy for cancer[J]. Cancer Biother Radiopharm, 2007, 22(5):573-584. DOI:10.1089/cbr.2006. 004-U.
[14] Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/neu-binding affibody ligands[J]. Protein Eng Des Sel, 2004, 17(5):455-462. DOI:10.1093/protein/gzh053.
[15] Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule[J]. Cancer Res, 2006, 66(8):4339-4348. DOI:10.1158/0008-5472. CAN-05-3521.
[16] Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules[J]. Bioconjug Chem, 2008, 19(1):235-243. DOI:10.1021/bc700307y.
[17] Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for affibody molecules[J]. J Mol Biol, 2010, 398(2):232-247. DOI:10.1016/j. jmb. 2010. 03. 002.
[18] L?fblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules:engineered proteins for therapeutic, diagnostic and biotechnological applications[J]. FEBS Lett, 2010, 584(12):2670-2680. DOI:10.1016/j. febslet. 2010. 04. 014.
[19] Luo TY, Cheng PC, Chiang PF, et al. 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells[J]. Ann Nucl Med, 2015, 29(1):52-62. DOI:10.1007/s12149-014-0908-8.
[20] Tolmachev V, W?llberg H, Andersson K, et al. The influence of Bz-DOTA and CHX-A"-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules:implications for 114mIn-mediated targeting therapy[J]. Eur J Nucl Med Mol Imaging, 2009, 36(9):1460-1468. DOI:10.1007/s00259-009-1134-9.
[21] Tran TA, Ekblad T, Orlova A, et al. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules[J]. Bioconjug Chem, 2008, 19(12):2568-2576. DOI:10.1021/bc800244b.
[22] Ahlgren S, W?llberg H, Tran TA, et al. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine[J]. J Nucl Med, 2009, 50(5):781-789. DOI:10.2967/jnumed. 108. 056929.
[23] Orlova A, Tolmachev V, Pehrson R, et al. Synthetic affibody molecules:a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors[J]. Cancer Res, 2007, 67(5):2178-2186. DOI:10.1158/0008-5472. CAN-06-2887.
[24] S?rensen J, Sandberg D, Sandstr?m M, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule[J]. J Nucl Med, 2014, 55(5):730-735. DOI:10. 2967/jnumed. 113. 131243.
[25] W?llberg H, Orlova A, Altai M, et al. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties[J]. J Nucl Med, 2011, 52(3):461-469. DOI:10. 2967/jnumed. 110. 083592.
[26] Zhang JM, Zhao XM, Wang SJ, et al. Evaluation of 99mTc-peptide-ZHER2:342 Affibody? molecule for in vivo molecular imaging[J/OL]. Br J Radiol, 2014, 87(133):20130484[2015-12-23]. http://www. ncbi. nlm. nih. gov/pmc/articles/PMC3898972. DOI:10.1259/bjr.20130484.
[27] 张敬勉, 赵新明, 王士杰, 等. 99Tcm标记人表皮生长因子受体2小分子靶向结合蛋白的制备及体外结合特性[J]. 中华核医学与分子影像杂志, 2014, 34(3):208-212. DOI:10. 3760/cma. j. issn. 2095-2848. 2014. 03. 012. Zhang JM, Zhao XM, Wang SJ, et al. Preparation and characterization of 99Tcm-labeled human epidemal growth factor type 2 affibody molecule in vitro[J]. Chin J Nucl Med Mol Imaging, 2014, 34(3):208-212.
[28] Zhang J, Zhao X, Wang S, et al. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with 99mTc-peptide-ZHER2:342[J]. Nucl Med Biol, 2015, 42(6):541-546. DOI:10.1016/j. nucmedbio. 2015. 02. 002.
[29] Kramer-Marek G, Shenoy N, Seidel J, et al. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET[J]. Eur J Nucl Med Mol Imaging, 2011, 38(11):1967-1976. DOI:10.1007/s00259-011-1810-4.
[30] Cheng Z, De Jesus OP, Kramer DJ, et al. 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors[J]. Mol Imaging Biol, 2010, 12(3):316-324. DOI:10.1007/s11307-009-0256-6.
[31] Kramer-Marek G, Bernardo M, Kiesewetter DO, et al. PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer:comparison with 18F-FDG[J]. J Nucl Med, 2012, 53(6):939-946. DOI:10.2967/jnumed.111.100354.
[32] Altai M, W?llberg H, Honarvar H, et al. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors:preclinical assessment[J]. J Nucl Med, 2014, 55(11):1842-1848. DOI:10. 2967/jnumed. 114. 140194.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[3]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[4]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[5]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[6]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[7]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[8]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
[9]黄丽娟,陈宁,叶静,等.反义肽核酸对促甲状腺激素受体mRNA表达的影响[J].国际放射医学核医学杂志,2012,36(5):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
HUANG Li-juan,CHEN Ning,YE Jing,et al.The effects of antisense peptide nucleic acid on the expression of thyroid stimulating hormone receptor mRNA[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
[10]刘淼,刘兴党.生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究[J].国际放射医学核医学杂志,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
LIU Miao,LIU Xing-dang.Development of study on SPECT imaging with radioisotope 99Tcm-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
[11]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[12]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[13]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
[14]王相成,王雪梅,何玉林,等.PET-CT表皮生长因子受体显像的研究进展[J].国际放射医学核医学杂志,2010,34(5):266.[doi:10.3760/cma.j.issn.1673-4114.2010.05.003]
WANG Xiang-cheng,WANG Xue-mei,HE Yu-lin,et al.Study progress of PET-CT epidermal growth factor receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):266.[doi:10.3760/cma.j.issn.1673-4114.2010.05.003]
[15]汪永红,陈文新,何品玉.肿瘤表皮生长因子受体的分子显像研究[J].国际放射医学核医学杂志,2009,33(4):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
WANG Yong-hong,CHEN Wen-xin,HE Pin-yu.Tumor epidermal growth factor receptor molecular imaging research[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
[16]黄顺,韩彦江,郑希,等.靶向表皮生长因子受体小分子类PET显像剂研究进展[J].国际放射医学核医学杂志,2017,41(1):50.[doi:10.3760/cma.j.issn.1673-4114.2017.01.010]
Huang Shun,Han Yanjiang,Zheng Xi,et al.PET imaging agents of small molecules inhibitors targeting EGFR[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(2):50.[doi:10.3760/cma.j.issn.1673-4114.2017.01.010]
[17]郑玉民,王自正,王峰,等.以表皮生长因子受体为靶点的肿瘤分子靶向治疗[J].国际放射医学核医学杂志,2007,31(1):21.
ZHENG Yu-min,WANG Zi-zheng,WANG Feng,et al.Epidermal growth factor receptor targeted molecularly therapies of cancers[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):21.
[18]袁卫红,罗志航,彭荣宗,等.肺癌与表皮生长因子及其受体关系的研究[J].国际放射医学核医学杂志,2006,30(5):261.
YUAN Wei-hong,LUO Zhi-hang,PENG Rong-zong,et al.The study on the correlation between EGF, EGFR and lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):261.
[19]何蕊,朱高红.甲状腺髓样癌靶向治疗的研究进展[J].国际放射医学核医学杂志,2018,(2):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]
He Rui,Zhu Gaohong.Research status of medullary thyroid carcinoma targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]